{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8"],"submitter":["Rahman MS"],"pubmed_abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent of the ongoing pandemic of coronavirus disease 2019 (COVID-19), a public health emergency of international concerns declared by the World Health Organization (WHO). An immuno-informatics approach along with comparative genomics was applied to design a multi-epitope-based peptide vaccine against SARS-CoV-2 combining the antigenic epitopes of the S, M, and E proteins. The tertiary structure was predicted, refined and validated using advanced bioinformatics tools. The candidate vaccine showed an average of ≥90.0% world population coverage for different ethnic groups. Molecular docking and dynamics simulation of the chimeric vaccine with the immune receptors (TLR3 and TLR4) predicted efficient binding. Immune s"],"journal":["PeerJ"],"pagination":["e9572"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7394063"],"repository":["biostudies-literature"],"pubmed_title":["Epitope-based chimeric peptide vaccine design against S, M and E proteins of SARS-CoV-2, the etiologic agent of COVID-19 pandemic: an in silico approach."],"pmcid":["PMC7394063"],"pubmed_authors":["Rubayet Ul Alam ASM","Islam MR","Siddique MA","Sultana M","Hossain MA","Akter S","Rahman MS","Rahaman MM","Crandall KA","Hoque MN","Saha O"],"additional_accession":[]},"is_claimable":false,"name":"Epitope-based chimeric peptide vaccine design against S, M and E proteins of SARS-CoV-2, the etiologic agent of COVID-19 pandemic: an in silico approach.","description":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent of the ongoing pandemic of coronavirus disease 2019 (COVID-19), a public health emergency of international concerns declared by the World Health Organization (WHO). An immuno-informatics approach along with comparative genomics was applied to design a multi-epitope-based peptide vaccine against SARS-CoV-2 combining the antigenic epitopes of the S, M, and E proteins. The tertiary structure was predicted, refined and validated using advanced bioinformatics tools. The candidate vaccine showed an average of ≥90.0% world population coverage for different ethnic groups. Molecular docking and dynamics simulation of the chimeric vaccine with the immune receptors (TLR3 and TLR4) predicted efficient binding. Immune s","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020","modification":"2026-05-02T23:43:18.72Z","creation":"2020-11-19T16:13:36Z"},"accession":"S-EPMC7394063","cross_references":{"pubmed":["33194329"],"doi":["10.7717/peerj.9572"]}}